{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:31:59Z","timestamp":1787923919450,"version":"build-2784847793"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Polish National Science Center","award":["2015\/17\/B\/NZ5\/00640"],"award-info":[{"award-number":["2015\/17\/B\/NZ5\/00640"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant chemotherapy (NACT) for early breast cancer is a systemic treatment administered before surgery to achieve regression of the primary lesion, perform breast-conserving surgery, if possible, and ensure long-term recurrence-free survival. The main aim of this study was to investigate the impact of NACT on the active DNA demethylation process and the relationship between the compounds involved in this path and disease-free survival (DFS) and overall survival (OS) during a six-year follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This study included 71 patients with breast cancer who were eligible for NACT consisting of 4 cycles of doxorubicin and cyclophosphamide regimens at doses of 60\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and 600\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , respectively, on the first day every 21\u00a0days, as well as paclitaxel administered at a dose of 80\u00a0mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      weekly for 12\u00a0weeks. Peripheral blood and urine samples were collected from breast cancer patients at four time points. Additionally, tissue samples from a breast cancer tumor and regional metastatic lymph nodes were collected during surgery. The levels of 5-methylcytosine (5-mCyt) and its derivatives in DNA and urine were determined via two-dimensional ultra-performance liquid chromatography with tandem mass spectrometry (2D-UPLC-MS\/MS). The qRT\u2012PCR technique was used to determine the transcript levels of the genes involved in active DNA demethylation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During chemotherapy, increases in the levels of 5-methyl-2\u02b9-deoxycytidine (5-mdC), 5-formyl-2\u02b9-deoxycytidine (5-fdC), and 5-carboxyl-2\u02b9-deoxycytidine (5-cadC) and decreases in the expression of genes encoding TET (ten-eleven translocation) proteins, TDG (thymine DNA glycosylase), and AID (activation-induced cytidine deaminase) were observed in peripheral blood leukocytes. The Kaplan\u2012Meier curves revealed that patients with a lower level of 5-mdC in leukocyte DNA and urine before NACT, higher levels of 5-cadC, and lower\n                      <jats:italic>TDG<\/jats:italic>\n                      expression in tumor cells after treatment had a more favorable prognosis. Furthermore, significant correlations were found between the levels of 5-fdC in the DNA of leukocytes, 5-cadC in DNA tumor cells, the expression of\n                      <jats:italic>TET2<\/jats:italic>\n                      , and decreased Ki-67 after NACT.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results indicate that NACT can alter active DNA demethylation markers. Breast cancer patients with prolonged DFS had lower leukocyte 5-mdC and higher urinary 5-mdC levels before chemotherapy. Thus, assessing 5-mdC in these minimally invasive biospecimens may provide prognostic information for breast cancer patients undergoing NACT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-026-02314-8","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T14:43:02Z","timestamp":1781793782000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Changes in active DNA demethylation pathway components during neoadjuvant chemotherapy and their prognostic significance in breast cancer"],"prefix":"10.1186","volume":"28","author":[{"given":"Jolanta","family":"Guz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Urbanowska-Domanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Zarakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gackowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Rozalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Linowiecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Skalska-Bugala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rhone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryszard","family":"Olinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1338-8230","authenticated-orcid":false,"given":"Marek","family":"Foksinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"10","key":"2314_CR1","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.3390\/cancers14102569","volume":"14","author":"B Smolarz","year":"2022","unstructured":"Smolarz B, Nowak AZ, Romanowicz H. Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature). Cancers (Basel). 2022;14(10):2569.","journal-title":"Cancers (Basel)"},{"key":"2314_CR2","first-page":"721","volume":"15","author":"J Wang","year":"2023","unstructured":"Wang J, Wu SG. Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives. Breast Cancer (Dove Med Press). 2023;15:721\u201330.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"2","key":"2314_CR3","first-page":"171","volume":"104","author":"KP Trayes","year":"2021","unstructured":"Trayes KP, Cokenakes SEH. Breast cancer treatment. Am Fam Physician. 2021;104(2):171\u20138.","journal-title":"Am Fam Physician"},{"issue":"4","key":"2314_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3390\/cancers14040971","volume":"14","author":"T Susini","year":"2022","unstructured":"Susini T, Biglia N, Bounous VE. Prognostic factors research in breast cancer patients: new paths. Cancers (Basel). 2022;14(4):971.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"2314_CR5","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","volume":"24","author":"M Kaufmann","year":"2006","unstructured":"Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006;24(12):1940\u20139.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2314_CR6","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/jclinpath-2012-201361","volume":"66","author":"SA O'Toole","year":"2013","unstructured":"O\u2019Toole SA, Beith JM, Millar EK, West R, McLean A, Cazet A, et al. Therapeutic targets in triple negative breast cancer. J Clin Pathol. 2013;66(6):530\u201342.","journal-title":"J Clin Pathol"},{"key":"2314_CR7","doi-asserted-by":"publisher","first-page":"117822342098037","DOI":"10.1177\/1178223420980377","volume":"14","author":"M Asaoka","year":"2020","unstructured":"Asaoka M, Gandhi S, Ishikawa T, Takabe K. Neoadjuvant chemotherapy for breast cancer: past, present, and future. Breast Cancer (Auckl). 2020;14:1178223420980377.","journal-title":"Breast Cancer (Auckl)"},{"issue":"6","key":"2314_CR8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1634\/theoncologist.9-6-606","volume":"9","author":"M Cianfrocca","year":"2004","unstructured":"Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist. 2004;9(6):606\u201316.","journal-title":"Oncologist"},{"issue":"6","key":"2314_CR9","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s11845-022-02926-x","volume":"191","author":"D Courtney","year":"2022","unstructured":"Courtney D, Davey MG, Moloney BM, Barry MK, Sweeney K, McLaughlin RP, et al. Breast cancer recurrence: factors impacting occurrence and survival. Ir J Med Sci. 2022;191(6):2501\u201310.","journal-title":"Ir J Med Sci"},{"issue":"24","key":"2314_CR10","doi-asserted-by":"publisher","first-page":"6357","DOI":"10.1158\/1078-0432.CCR-14-0297","volume":"20","author":"J Klajic","year":"2014","unstructured":"Klajic J, Busato F, Edvardsen H, Touleimat N, Fleischer T, Bukholm I, et al. DNA methylation status of key cell-cycle regulators such as CDKNA2\/p16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors. Clin Cancer Res. 2014;20(24):6357\u201366.","journal-title":"Clin Cancer Res"},{"key":"2314_CR11","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fmolb.2020.00118","volume":"7","author":"XP Liu","year":"2020","unstructured":"Liu XP, Hou J, Chen C, Guan L, Hu HK, Li S. A DNA methylation-based panel for the prognosis and Dagnosis of patients with breast cancer and its mechanisms. Front Mol Biosci. 2020;7:118.","journal-title":"Front Mol Biosci"},{"issue":"10","key":"2314_CR12","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1038\/bjc.2013.136","volume":"108","author":"AQ van Hoesel","year":"2013","unstructured":"van Hoesel AQ, Sato Y, Elashoff DA, Turner RR, Giuliano AE, Shamonki JM, et al. Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer. 2013;108(10):2033\u20138.","journal-title":"Br J Cancer"},{"issue":"8","key":"2314_CR13","doi-asserted-by":"publisher","first-page":"e103896","DOI":"10.1371\/journal.pone.0103896","volume":"9","author":"M Reyngold","year":"2014","unstructured":"Reyngold M, Turcan S, Giri D, Kannan K, Walsh LA, Viale A, et al. Remodeling of the methylation landscape in breast cancer metastasis. PLoS ONE. 2014;9(8):e103896.","journal-title":"PLoS ONE"},{"issue":"1","key":"2314_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ijc.29684","volume":"138","author":"B Gyorffy","year":"2016","unstructured":"Gyorffy B, Bottai G, Fleischer T, Munkacsy G, Budczies J, Paladini L, et al. Aberrant DNA methylation impacts gene expression and prognosis in breast cancer subtypes. Int J Cancer. 2016;138(1):87\u201397.","journal-title":"Int J Cancer"},{"key":"2314_CR15","doi-asserted-by":"publisher","first-page":"102430","DOI":"10.1016\/j.sbi.2022.102430","volume":"75","author":"S Li","year":"2022","unstructured":"Li S, Peng Y, Panchenko AR. DNA methylation: precise modulation of chromatin structure and dynamics. Curr Opin Struct Biol. 2022;75:102430.","journal-title":"Curr Opin Struct Biol"},{"key":"2314_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.gde.2016.01.004","volume":"36","author":"J Jeschke","year":"2016","unstructured":"Jeschke J, Collignon E, Fuks F. Portraits of TET-mediated DNA hydroxymethylation in cancer. Curr Opin Genet Dev. 2016;36:16\u201326.","journal-title":"Curr Opin Genet Dev"},{"issue":"1","key":"2314_CR17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13073-015-0134-6","volume":"7","author":"L Scourzic","year":"2015","unstructured":"Scourzic L, Mouly E, Bernard OA. TET proteins and the control of cytosine demethylation in cancer. Genome Med. 2015;7(1):9.","journal-title":"Genome Med"},{"issue":"1","key":"2314_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bies.201600178","volume":"39","author":"M Bochtler","year":"2017","unstructured":"Bochtler M, Kolano A, Xu GL. DNA demethylation pathways: additional players and regulators. BioEssays. 2017;39(1):1\u201313.","journal-title":"BioEssays"},{"issue":"7","key":"2314_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/nchembio.1532","volume":"10","author":"T Pfaffeneder","year":"2014","unstructured":"Pfaffeneder T, Spada F, Wagner M, Brandmayr C, Laube SK, Eisen D, et al. Tet oxidizes thymine to 5-hydroxymethyluracil in mouse embryonic stem cell DNA. Nat Chem Biol. 2014;10(7):574\u201381.","journal-title":"Nat Chem Biol"},{"issue":"6","key":"2314_CR20","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.cell.2011.08.042","volume":"146","author":"N Bhutani","year":"2011","unstructured":"Bhutani N, Burns DM, Blau HM. DNA demethylation dynamics. Cell. 2011;146(6):866\u201372.","journal-title":"Cell"},{"issue":"1","key":"2314_CR21","doi-asserted-by":"publisher","first-page":"e10033","DOI":"10.1002\/ggn2.10033","volume":"2","author":"R Prasad","year":"2021","unstructured":"Prasad R, Yen TJ, Bellacosa A. Active DNA demethylation-the epigenetic gatekeeper of development, immunity, and cancer. Adv Genet (Hoboken). 2021;2(1):e10033.","journal-title":"Adv Genet (Hoboken)"},{"issue":"1\u20132","key":"2314_CR22","first-page":"58","volume":"574","author":"MS Cooke","year":"2005","unstructured":"Cooke MS, Evans MD, Dove R, Rozalski R, Gackowski D, Siomek A, et al. DNA repair is responsible for the presence of oxidatively damaged DNA lesions in urine. Mutat Res. 2005;574(1\u20132):58\u201366.","journal-title":"Mutat Res"},{"issue":"11","key":"2314_CR23","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1080\/10715760400017350","volume":"38","author":"R Rozalski","year":"2004","unstructured":"Rozalski R, Siomek A, Gackowski D, Foksinski M, Gran C, Klungland A, et al. Diet is not responsible for the presence of several oxidatively damaged DNA lesions in mouse urine. Free Radic Res. 2004;38(11):1201\u20135.","journal-title":"Free Radic Res"},{"issue":"8","key":"2314_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.tips.2014.05.004","volume":"35","author":"M Ivanov","year":"2014","unstructured":"Ivanov M, Barragan I, Ingelman-Sundberg M. Epigenetic mechanisms of importance for drug treatment. Trends Pharmacol Sci. 2014;35(8):384\u201396.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"2314_CR25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-015-2951-0","volume":"77","author":"JF Lv","year":"2016","unstructured":"Lv JF, Hu L, Zhuo W, Zhang CM, Zhou HH, Fan L. Epigenetic alternations and cancer chemotherapy response. Cancer Chemother Pharmacol. 2016;77(4):673\u201384.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2314_CR26","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.3389\/fonc.2020.01152","volume":"10","author":"S Romero-Garcia","year":"2020","unstructured":"Romero-Garcia S, Prado-Garcia H, Carlos-Reyes A. Role of DNA methylation in the resistance to therapy in solid tumors. Front Oncol. 2020;10:1152.","journal-title":"Front Oncol"},{"issue":"24","key":"2314_CR27","doi-asserted-by":"publisher","first-page":"12128","DOI":"10.1021\/acs.analchem.6b02900","volume":"88","author":"D Gackowski","year":"2016","unstructured":"Gackowski D, Starczak M, Zarakowska E, Modrzejewska M, Szpila A, Banaszkiewicz Z, et al. Accurate, direct, and high-throughput analyses of a broad spectrum of endogenously generated DNA base modifications with isotope-dilution two-dimensional ultraperformance liquid chromatography with tandem mass spectrometry: possible clinical implication. Anal Chem. 2016;88(24):12128\u201336.","journal-title":"Anal Chem"},{"key":"2314_CR28","doi-asserted-by":"crossref","unstructured":"Starczak M, Gawronski M, Olinski R, Gackowski D: Quantification of DNA modifications using two-dimensional ultraperformance liquid chromatography tandem mass spectrometry (2D-UPLC-MS\/MS). DNA Modifications: Methods and Protocols 2021:91\u2013108.","DOI":"10.1007\/978-1-0716-0876-0_8"},{"key":"2314_CR29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/978-1-0716-0876-0_9","volume-title":"DNA modifications: methods and protocols","author":"A Skalska","year":"2021","unstructured":"Skalska A, Siomek-Gorecka A, Olinski R, Rozalski R. MS analysis of DNA modifications in urinary\/body fluids. In: Ruzov A, Gering M, editors. DNA modifications: methods and protocols. New York, NY: Springer US; 2021. p. 109\u201322."},{"issue":"1","key":"2314_CR30","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13148-019-0641-1","volume":"11","author":"S Yao","year":"2019","unstructured":"Yao S, Hu Q, Kerns S, Yan L, Onitilo AA, Misleh J, et al. Impact of chemotherapy for breast cancer on leukocyte DNA methylation landscape and cognitive function: a prospective study. Clin Epigenetics. 2019;11(1):45.","journal-title":"Clin Epigenetics"},{"key":"2314_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.bbi.2014.02.010","volume":"38","author":"AK Smith","year":"2014","unstructured":"Smith AK, Conneely KN, Pace TW, Mister D, Felger JC, Kilaru V, et al. Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy. Brain Behav Immun. 2014;38:227\u201336.","journal-title":"Brain Behav Immun"},{"issue":"1","key":"2314_CR32","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13058-023-01730-4","volume":"25","author":"PJ Ho","year":"2023","unstructured":"Ho PJ, Khng AJ, Tan BK, Lim GH, Tan SM, Tan VKM, et al. Alterations to DNA methylation patterns induced by chemotherapy treatment are associated with negative impacts on the olfactory pathway. Breast Cancer Res. 2023;25(1):136.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"2314_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13058-022-01537-9","volume":"24","author":"CA Pedersen","year":"2022","unstructured":"Pedersen CA, Cao MD, Fleischer T, Rye MB, Knappskog S, Eikesdal HP, et al. DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival. Breast Cancer Res. 2022;24(1):43.","journal-title":"Breast Cancer Res"},{"issue":"6","key":"2314_CR34","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1007\/s13277-012-0443-y","volume":"33","author":"G Sharma","year":"2012","unstructured":"Sharma G, Mirza S, Parshad R, Gupta SD, Ralhan R. DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol. 2012;33(6):1837\u201343.","journal-title":"Tumour Biol"},{"issue":"7","key":"2314_CR35","doi-asserted-by":"publisher","first-page":"E1166","DOI":"10.1002\/ijc.27526","volume":"131","author":"A Avraham","year":"2012","unstructured":"Avraham A, Uhlmann R, Shperber A, Birnbaum M, Sandbank J, Sella A, et al. Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients. Int J Cancer. 2012;131(7):E1166-1172.","journal-title":"Int J Cancer"},{"issue":"9","key":"2314_CR36","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1158\/1078-0432.CCR-16-1754","volume":"23","author":"JM Flanagan","year":"2017","unstructured":"Flanagan JM, Wilson A, Koo C, Masrour N, Gallon J, Loomis E, et al. Platinum-based chemotherapy induces methylation changes in blood DNA associated with overall survival in patients with ovarian cancer. Clin Cancer Res. 2017;23(9):2213\u201322.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2314_CR37","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1080\/15216540701697412","volume":"59","author":"AM Barciszewska","year":"2007","unstructured":"Barciszewska AM, Murawa D, Gawronska I, Murawa P, Nowak S, Barciszewska MZ. Analysis of 5-methylcytosine in DNA of breast and colon cancer tissues. IUBMB Life. 2007;59(12):765\u201370.","journal-title":"IUBMB Life"},{"issue":"3","key":"2314_CR38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/ijc.25365","volume":"128","author":"Y Zhang","year":"2011","unstructured":"Zhang Y, Gao Y, Zhang G, Huang S, Dong Z, Kong C, et al. DNMT3a plays a role in switches between doxorubicin-induced senescence and apoptosis of colorectal cancer cells. Int J Cancer. 2011;128(3):551\u201361.","journal-title":"Int J Cancer"},{"key":"2314_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s13578-019-0278-y","volume":"9","author":"Y Luo","year":"2019","unstructured":"Luo Y, Huang J, Tang Y, Luo X, Ge L, Sheng X, et al. Regional methylome profiling reveals dynamic epigenetic heterogeneity and convergent hypomethylation of stem cell quiescence-associated genes in breast cancer following neoadjuvant chemotherapy. Cell Biosci. 2019;9:16.","journal-title":"Cell Biosci"},{"issue":"41","key":"2314_CR40","doi-asserted-by":"publisher","first-page":"35334","DOI":"10.1074\/jbc.C111.284620","volume":"286","author":"A Maiti","year":"2011","unstructured":"Maiti A, Drohat AC. Thymine DNA glycosylase can rapidly excise 5-formylcytosine and 5-carboxylcytosine: potential implications for active demethylation of CpG sites. J Biol Chem. 2011;286(41):35334\u20138.","journal-title":"J Biol Chem"},{"issue":"7","key":"2314_CR41","doi-asserted-by":"publisher","first-page":"e97754","DOI":"10.1371\/journal.pone.0097754","volume":"9","author":"DM Franchini","year":"2014","unstructured":"Franchini DM, Chan CF, Morgan H, Incorvaia E, Rangam G, Dean W, et al. Processive DNA demethylation via DNA deaminase-induced lesion resolution. PLoS ONE. 2014;9(7):e97754.","journal-title":"PLoS ONE"},{"issue":"8","key":"2314_CR42","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1093\/nar\/gkw059","volume":"44","author":"I Grin","year":"2016","unstructured":"Grin I, Ishchenko AA. An interplay of the base excision repair and mismatch repair pathways in active DNA demethylation. Nucleic Acids Res. 2016;44(8):3713\u201327.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2314_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13148-018-0540-x","volume":"10","author":"TM Storebjerg","year":"2018","unstructured":"Storebjerg TM, Strand SH, Hoyer S, Lynnerup AS, Borre M, Orntoft TF, et al. Dysregulation and prognostic potential of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC) levels in prostate cancer. Clin Epigenetics. 2018;10(1):105.","journal-title":"Clin Epigenetics"},{"issue":"10","key":"2314_CR44","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.tibs.2013.07.003","volume":"38","author":"CX Song","year":"2013","unstructured":"Song CX, He C. Potential functional roles of DNA demethylation intermediates. Trends Biochem Sci. 2013;38(10):480\u20134.","journal-title":"Trends Biochem Sci"},{"issue":"6","key":"2314_CR45","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/j.jmb.2019.07.039","volume":"432","author":"GP Pfeifer","year":"2020","unstructured":"Pfeifer GP, Szabo PE, Song J. Protein interactions at oxidized 5-methylcytosine bases. J Mol Biol. 2020;432(6):1718\u201330.","journal-title":"J Mol Biol"},{"issue":"5","key":"2314_CR46","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/nar\/gkw1184","volume":"45","author":"D Wang","year":"2017","unstructured":"Wang D, Hashimoto H, Zhang X, Barwick BG, Lonial S, Boise LH, et al. MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma. Nucleic Acids Res. 2017;45(5):2396\u2013407.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2314_CR47","doi-asserted-by":"publisher","first-page":"e0133896","DOI":"10.1371\/journal.pone.0133896","volume":"10","author":"L Yang","year":"2015","unstructured":"Yang L, Yu SJ, Hong Q, Yang Y, Shao ZM. Reduced expression of TET1, TET2, TET3 and TDG mRNAs are associated with poor prognosis of patients with early breast cancer. PLoS ONE. 2015;10(7):e0133896.","journal-title":"PLoS ONE"},{"issue":"7","key":"2314_CR48","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"CF Thorn","year":"2011","unstructured":"Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE, et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics. 2011;21(7):440\u20136.","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"2314_CR49","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ccr.2011.09.012","volume":"20","author":"HM O'Hagan","year":"2011","unstructured":"O\u2019Hagan HM, Wang W, Sen S, Destefano Shields C, Lee SS, Zhang YW, et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and polycomb members to promoter CpG islands. Cancer Cell. 2011;20(5):606\u201319.","journal-title":"Cancer Cell"},{"key":"2314_CR50","doi-asserted-by":"crossref","unstructured":"Onabote O, Hassan HM, Isovic M, Torchia J: The Role of Thymine DNA Glycosylase in Transcription, Active DNA Demethylation, and Cancer. Cancers (Basel) 2022, 14(3).","DOI":"10.3390\/cancers14030765"},{"issue":"6","key":"2314_CR51","doi-asserted-by":"publisher","first-page":"986","DOI":"10.4062\/biomolther.2025.143","volume":"33","author":"KA Kang","year":"2025","unstructured":"Kang KA, Piao MJ, Senavirathna H, Boo HJ, Yoon SP, Yi JM, et al. Involvement of the DNA demethylase thymine DNA glycosylase in anticancer drug resistance. Biomol Ther (Seoul). 2025;33(6):986\u20131003.","journal-title":"Biomol Ther (Seoul)"},{"issue":"5","key":"2314_CR52","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1042\/EBC20200013","volume":"64","author":"GJ Grundy","year":"2020","unstructured":"Grundy GJ, Parsons JL. Base excision repair and its implications to cancer therapy. Essays Biochem. 2020;64(5):831\u201343.","journal-title":"Essays Biochem"},{"issue":"24","key":"2314_CR53","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.4161\/cc.22843","volume":"11","author":"NM da Costa","year":"2012","unstructured":"da Costa NM, Hautefeuille A, Cros MP, Melendez ME, Waters T, Swann P, et al. Transcriptional regulation of thymine DNA glycosylase (TDG) by the tumor suppressor protein p53. Cell Cycle. 2012;11(24):4570\u20138.","journal-title":"Cell Cycle"},{"issue":"9","key":"2314_CR54","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/jcb.25162","volume":"116","author":"E Tormo","year":"2015","unstructured":"Tormo E, Pineda B, Serna E, Guijarro A, Ribas G, Fores J, et al. MicroRNA profile in response to Doxorubicin treatment in breast cancer. J Cell Biochem. 2015;116(9):2061\u201373.","journal-title":"J Cell Biochem"},{"issue":"7","key":"2314_CR55","doi-asserted-by":"publisher","first-page":"941","DOI":"10.17219\/acem\/70745","volume":"27","author":"F Asghari","year":"2018","unstructured":"Asghari F, Haghnavaz N, Shanehbandi D, Khaze V, Baradaran B, Kazemi T. Differential altered expression of let-7a and miR-205 tumor-suppressor miRNAs in different subtypes of breast cancer under treatment with Taxol. Adv Clin Exp Med. 2018;27(7):941\u20135.","journal-title":"Adv Clin Exp Med"},{"issue":"3","key":"2314_CR56","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.bbrc.2013.06.082","volume":"437","author":"P Zhang","year":"2013","unstructured":"Zhang P, Huang B, Xu X, Sessa WC. Ten-eleven translocation (Tet) and thymine DNA glycosylase (TDG), components of the demethylation pathway, are direct targets of miRNA-29a. Biochem Biophys Res Commun. 2013;437(3):368\u201373.","journal-title":"Biochem Biophys Res Commun"},{"key":"2314_CR57","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21037\/ncri.2018.03.03","volume":"2","author":"K Sakurai","year":"2018","unstructured":"Sakurai K, Tsukamoto T. Unveiling the protein coding-independent function of the TET family in gastric cancer. Non-coding RNA Investig. 2018;2:17\u201317.","journal-title":"Non-coding RNA Investig"},{"issue":"2","key":"2314_CR58","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.cell.2013.06.026","volume":"154","author":"SJ Song","year":"2013","unstructured":"Song SJ, Poliseno L, Song MS, Ala U, Webster K, Ng C, et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell. 2013;154(2):311\u201324.","journal-title":"Cell"},{"key":"2314_CR59","doi-asserted-by":"crossref","unstructured":"Salmeron-Barcenas EG, Zacapala-Gomez AE, Torres-Rojas FI, Antonio-Vejar V, Avila-Lopez PA, Banos-Hernandez CJ, Nunez-Martinez HN, Dircio-Maldonado R, Martinez-Carrillo DN, Ortiz-Ortiz J et al: TET Enzymes and 5hmC Levels in Carcinogenesis and Progression of Breast Cancer: Potential Therapeutic Targets. Int J Mol Sci 2023, 25(1).","DOI":"10.3390\/ijms25010272"},{"issue":"1","key":"2314_CR60","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13048-019-0575-4","volume":"12","author":"T Cao","year":"2019","unstructured":"Cao T, Pan W, Sun X, Shen H. Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis. J Ovarian Res. 2019;12(1):101.","journal-title":"J Ovarian Res"},{"issue":"2","key":"2314_CR61","doi-asserted-by":"publisher","first-page":"e1542918","DOI":"10.1080\/2162402X.2018.1542918","volume":"8","author":"AA Elashi","year":"2019","unstructured":"Elashi AA, Sasidharan Nair V, Taha RZ, Shaath H, Elkord E. DNA methylation of immune checkpoints in the peripheral blood of breast and colorectal cancer patients. Oncoimmunology. 2019;8(2):e1542918.","journal-title":"Oncoimmunology"},{"key":"2314_CR62","doi-asserted-by":"crossref","unstructured":"Shen Y, Liu L, Wang M, Xu B, Lyu R, Shi YG, Tan L: TET2 Inhibits PD-L1 Gene Expression in Breast Cancer Cells through Histone Deacetylation. Cancers (Basel) 2021, 13(9).","DOI":"10.3390\/cancers13092207"},{"issue":"10","key":"2314_CR63","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1158\/0008-5472.CAN-16-0707","volume":"77","author":"M Sobecki","year":"2017","unstructured":"Sobecki M, Mrouj K, Colinge J, Gerbe F, Jay P, Krasinska L, et al. Cell-cycle regulation accounts for variability in Ki-67 expression levels. Cancer Res. 2017;77(10):2722\u201334.","journal-title":"Cancer Res"},{"issue":"3","key":"2314_CR64","doi-asserted-by":"publisher","first-page":"575","DOI":"10.20892\/j.issn.2095-3941.2018.0423","volume":"16","author":"C Chen","year":"2019","unstructured":"Chen C, Zhang Y, Huang Z, Wu J, Huang W, Zhang G. Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer. Cancer Biol Med. 2019;16(3):575\u201386.","journal-title":"Cancer Biol Med"},{"key":"2314_CR65","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.humpath.2017.02.005","volume":"63","author":"E Tokuda","year":"2017","unstructured":"Tokuda E, Horimoto Y, Arakawa A, Himuro T, Senuma K, Nakai K, et al. Differences in Ki67 expressions between pre- and post-neoadjuvant chemotherapy specimens might predict early recurrence of breast cancer. Hum Pathol. 2017;63:40\u20135.","journal-title":"Hum Pathol"},{"issue":"8","key":"2314_CR66","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.4161\/epi.29632","volume":"9","author":"BM Lindqvist","year":"2014","unstructured":"Lindqvist BM, Wingren S, Motlagh PB, Nilsson TK. Whole genome DNA methylation signature of HER2-positive breast cancer. Epigenetics. 2014;9(8):1149\u201362.","journal-title":"Epigenetics"},{"key":"2314_CR67","doi-asserted-by":"publisher","first-page":"1610093","DOI":"10.3389\/fonc.2025.1610093","volume":"15","author":"Z Guo","year":"2025","unstructured":"Guo Z, Wei J, Gui A, Liang X, Yu P, Bai J, et al. Analysis of methylation features associated with neoadjuvant efficacy in HER2-positive breast cancer. Front Oncol. 2025;15:1610093.","journal-title":"Front Oncol"},{"issue":"7","key":"2314_CR68","doi-asserted-by":"publisher","first-page":"e41361","DOI":"10.1371\/journal.pone.0041361","volume":"7","author":"LE Reinius","year":"2012","unstructured":"Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahlen SE, Greco D, et al. Differential DNA methylation in purified human blood cells: Implications for cell lineage and studies on disease susceptibility. PLoS ONE. 2012;7(7):e41361.","journal-title":"PLoS ONE"},{"issue":"8","key":"2314_CR69","doi-asserted-by":"publisher","first-page":"816","DOI":"10.4161\/epi.25430","volume":"8","author":"DC Koestler","year":"2013","unstructured":"Koestler DC, Christensen B, Karagas MR, Marsit CJ, Langevin SM, Kelsey KT, et al. Blood-based profiles of DNA methylation predict the underlying distribution of cell types: A validation analysis. Epigenetics. 2013;8(8):816\u201326.","journal-title":"Epigenetics"},{"key":"2314_CR70","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1471-2105-13-86","volume":"13","author":"EA Houseman","year":"2012","unstructured":"Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics. 2012;13:86.","journal-title":"BMC Bioinformatics"},{"key":"2314_CR71","doi-asserted-by":"crossref","unstructured":"Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, Pirkle JL: Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect 2005, 113(2):192\u2013200.","DOI":"10.1289\/ehp.7337"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-026-02314-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02314-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-026-02314-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:04:24Z","timestamp":1787922264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13058-026-02314-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2314"],"URL":"https:\/\/doi.org\/10.1186\/s13058-026-02314-8","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, its protocol was approved by the Local Bioethics Committee at Collegium Medicum, Nicolaus Copernicus University in Bydgoszcz, Poland (KB 806\/2015), and written informed consent was obtained from all the subjects.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"150"}}